Trial Profile

A Phase 2 combination trial evaluating D3S-001 (elisrasib) in combination with D3S-002

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 16 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs D3S-002 (Primary) ; Elisrasib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

16 Feb 2026 New trial record
19 Jan 2026 According to D3 Bio media release, company announced that the U.S. Food and Drug Administration (FDA) has cleared Investigational New Drug (IND) applications for a Phase 2 combination trial evaluating D3S-001 (elisrasib) in combination with D3S-002, a selective oral ERK1/2 inhibitor. The trial, expected to begin in the first half of 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com